GLP-1 Hair Loss: Temporary Hair Shedding on Semaglutide and Tirzepatide

Weight Loss
Written By Chris Lyons

Medically reviewed by Dr. Michael Koehler, MD

Some patients taking semaglutide or tirzepatide notice increased hair shedding as they lose weight. This can be alarming, especially when treatment is otherwise working well.

The most common pattern associated with significant or rapid weight loss is telogen effluvium, a temporary, non-scarring form of diffuse hair shedding. Telogen effluvium is well recognized after major physiologic changes, including substantial weight loss, illness, surgery, and bariatric procedures. It is very different from the type of hair loss associated with chemotherapy.

Recent research, including large studies published in 2026, has strengthened the evidence that GLP-1-based medications are associated with a small increase in the risk of non-scarring hair loss. However, an important question remains unanswered: Is the medication itself causing hair loss, or is shedding primarily related to weight loss, reduced calorie intake, nutritional changes, and other physiologic effects of treatment?

GLP-1 Hair Loss

For many patients, the clinical picture is consistent with telogen effluvium. Shedding may begin several weeks to a few months after significant weight loss and often improves once weight, nutrition, and the underlying physiologic stress stabilize.

What Is Telogen Effluvium?

Hair follicles continuously move through different stages of a natural growth cycle. These include the active growth phase, known as anagen, followed by transition and resting phases.

Normally, only a portion of scalp hairs are resting at any given time. After a significant physiologic stressor, however, a larger number of follicles can shift into the resting, or telogen, phase at approximately the same time.

Those hairs eventually shed, which is why hair loss may not appear immediately after the triggering event.

Significant or rapid weight loss is one recognized trigger.

Hair is also metabolically active and composed largely of the protein keratin. During GLP-1 treatment, appetite and overall food intake can decrease substantially. Some patients may find it difficult to consume adequate protein and nutrient-dense foods, particularly if they experience nausea, early satiety, or other gastrointestinal side effects.

For this reason, nutrition is an important part of evaluating hair shedding during medical weight loss.

Does Semaglutide or Tirzepatide Directly Cause Hair Loss?

It is not yet clear whether semaglutide or tirzepatide directly causes hair loss.

Observational research has found an association between GLP-1 medications and an increased risk of non-scarring alopecia. However, these studies cannot completely separate the effects of the medication from other factors that accompany substantial weight loss.

Potential contributors include:

  • Rapid or substantial weight loss

  • Reduced calorie intake

  • Inadequate protein or overall nutrition

  • Changes in iron or other nutrient status

  • Physiologic stress associated with major weight change

  • An underlying predisposition to androgenetic, or pattern, hair loss

A large 2026 BMJ study, for example, found a higher relative risk of non-scarring alopecia among adults with type 2 diabetes who initiated GLP-1 receptor agonists compared with patients starting certain other diabetes medications.

Importantly, that study examined people with type 2 diabetes. Affinity Whole Health's GLP-1 program is focused on medical weight management rather than diabetes treatment, so these findings cannot automatically be applied to patients without diabetes using GLP-1-based medications for weight loss.

The researchers also emphasized that although relative risk was increased, the absolute risk of alopecia remained low.

A separate 2026 cohort study published in the Journal of the American Academy of Dermatology examined new-onset hair loss among people receiving semaglutide or tirzepatide, adding to the evidence that this is an issue clinicians should monitor.

At this point, the most accurate conclusion is that hair shedding can occur during GLP-1 treatment, but research has not established that these medications directly damage hair follicles.

What Does Rapid Weight Loss Have to Do With Hair Shedding?

Weight loss itself has long been associated with telogen effluvium, even in people who are not taking GLP-1 medications.

A retrospective study of 140 patients with telogen effluvium associated with weight loss found that affected patients had lost an average of approximately 15% of their body weight, at an average rate of approximately 3.5 kg, or 7.8 pounds, per month.

These numbers should not be interpreted as thresholds at which hair loss will occur. They were averages among patients who had already developed telogen effluvium.

The study nevertheless reinforces an important clinical point: substantial and rapid changes in body weight can act as a physiologic stressor capable of disrupting the normal hair-growth cycle.

This phenomenon has also been observed following bariatric surgery and other forms of significant weight loss.

How Common Is Hair Loss on GLP-1 Therapy?

Most people taking GLP-1-based weight-loss medications do not experience clinically significant hair shedding.

Hair loss has, however, appeared in clinical trial data.

For example, prescribing information for semaglutide 2.4 mg has reported hair loss more frequently among participants receiving semaglutide than among those receiving placebo.

More recent real-world studies have also identified an association between GLP-1 medications and non-scarring alopecia.

However, interpreting these numbers requires caution.

Someone losing a substantial amount of weight while taking semaglutide or tirzepatide is experiencing several changes simultaneously. Medication exposure, calorie reduction, changes in protein intake, weight loss itself, hormonal changes, and underlying genetic susceptibility may all contribute.

Observational studies cannot completely separate these factors.

For this reason, telogen effluvium is better viewed as a recognized potential complication of substantial or rapid weight loss rather than proof that GLP-1 medications are toxic to hair follicles.

Can GLP-1 Weight Loss Unmask Pattern Hair Loss?

Sometimes.

Telogen effluvium generally causes diffuse shedding across the scalp rather than isolated bald patches.

However, an episode of significant shedding can make previously subtle androgenetic alopecia, commonly called male or female pattern hair loss, more noticeable.

Someone who already has a genetic predisposition to pattern hair loss may therefore notice that their hair does not completely return to its previous density after an episode of telogen effluvium.

This is one reason persistent hair loss should be evaluated rather than automatically attributed to GLP-1 treatment.

What Usually Happens Over Time?

Telogen effluvium generally does not begin immediately after the triggering event.

Hair shedding may become noticeable several weeks to a few months after significant weight loss or another physiologic stressor.

Once the underlying trigger improves and weight and nutritional intake become more stable, follicles can gradually return to their normal growth cycle.

Visible improvement takes time because hair grows slowly.

Patients may continue noticing shedding for several months, and visible regrowth can take six months or longer to become obvious.

Hair shedding also does not automatically mean semaglutide or tirzepatide needs to be discontinued.

Instead, significant shedding should be discussed with a medical provider so the rate of weight loss, nutritional intake, medication dosing, underlying health conditions, and other possible causes of hair loss can be evaluated before treatment changes are made.

How We Approach Hair Shedding at Affinity Whole Health

At Affinity Whole Health, we believe patients should know that temporary hair shedding can occur during significant weight loss before it becomes a source of unnecessary alarm.

Our approach focuses on identifying the likely cause, supporting nutrition, maintaining an appropriate rate of weight loss, and considering additional treatment when appropriate.

1. Evaluate the Pattern of Hair Loss

Diffuse shedding after substantial weight loss may be consistent with telogen effluvium, but not every case of hair loss should automatically be blamed on GLP-1 therapy.

We look at the timing and pattern of hair loss and consider whether another explanation may be contributing.

Depending on the individual situation, additional evaluation may be appropriate for potential contributors such as iron deficiency, thyroid dysfunction, nutritional deficiencies, or underlying pattern hair loss.

Patchy bald spots, significant scalp inflammation, eyebrow loss, scarring, or other unusual symptoms deserve further evaluation and may warrant referral to a dermatologist.

2. Protect Protein and Overall Nutrition

Adequate nutrition is an important part of medical weight management.

Because GLP-1 medications can significantly reduce appetite, patients may unintentionally reduce protein and overall nutrient intake too aggressively.

We pay particular attention to maintaining adequate protein while losing weight. Protein is important not only for hair but also for preserving lean body mass during weight reduction.

We discuss this in more detail in our guide toprotein during GLP-1 weight loss.

The goal is not simply to eat as little as possible. Effective medical weight management should prioritize nutrient-dense foods and adequate nutrition while creating an appropriate calorie deficit.

A multivitamin may be reasonable for some patients, but supplements should not be viewed as a substitute for adequate nutrition or as a guaranteed treatment for hair loss.

3. Consider the Rate of Weight Loss

Faster is not always better.

If someone is losing weight very rapidly while experiencing substantial hair shedding, their treatment plan may deserve another look.

Depending on the patient's response, nutritional intake, side effects, and overall goals, a provider may consider whether adjustments to dosing or the pace of weight loss are appropriate.

This does not mean patients should independently reduce or discontinue medication because they notice hair shedding.

Treatment adjustments should be made with their healthcare provider.

4. Support Hair Regrowth When Appropriate

For selected patients, additional hair-loss treatment may be considered after medical evaluation.

Affinity Whole Health does not prescribe finasteride or dutasteride.

We do offerlow-dose oral minoxidil for appropriately selected patients.

Low-dose oral minoxidil may be considered when shedding is slow to resolve or when evaluation suggests that an underlying pattern of androgenetic hair loss may also be present.

Minoxidil is not appropriate for everyone. Whether it makes sense depends on the patient's medical history, hair-loss pattern, medications, and other individual factors.

5. Keep the Bigger Picture in View

Temporary hair shedding can be frustrating, but it should be considered in the context of the patient's overall treatment response.

For many appropriate medical weight-management patients, temporary shedding can be managed without abandoning otherwise effective GLP-1 treatment.

The decision should be individualized based on the severity and duration of hair loss, nutritional status, rate of weight loss, treatment response, other potential causes of shedding, and the patient's overall goals.

Regular follow-up gives us an opportunity to make those adjustments rather than treating weight loss, nutrition, body composition, and hair health as separate issues.

When Should Hair Loss Be Evaluated Further?

Contact your healthcare provider or consider seeing a dermatologist if:

  • Hair loss occurs in patches rather than diffusely across the scalp

  • Shedding remains significant after weight and nutrition have stabilized

  • Hair loss continues for more than approximately six months

  • Your scalp is painful, inflamed, burning, intensely itchy, or showing signs of scarring

  • You are also losing eyebrow or other body hair

  • You notice a progressively widening part or receding hairline that could indicate pattern hair loss

  • You have other symptoms that could suggest an underlying nutritional, thyroid, hormonal, or medical issue

These features may point to something other than straightforward telogen effluvium.

Can You Prevent Hair Loss While Taking Semaglutide or Tirzepatide?

There is no guaranteed way to prevent telogen effluvium, but several practical steps may help reduce avoidable contributors to shedding.

Patients undergoing medical weight loss should focus on adequate protein, nutrient-dense foods, an appropriate rate of weight loss, management of significant gastrointestinal side effects, and regular medical follow-up.

Avoid automatically adding high-dose vitamins or hair supplements without identifying a deficiency. More is not necessarily better, and excessive intake of certain nutrients can cause problems of its own.

Most importantly, tell your provider if your appetite has become so suppressed that you are struggling to meet basic nutritional needs.

Bottom Line

Temporary hair shedding can occur during weight loss with semaglutide, tirzepatide, and other GLP-1-based treatments.

In many cases, the pattern is consistent with telogen effluvium, a temporary, non-scarring form of hair loss that can follow significant or rapid weight loss.

Current research has identified an association between GLP-1 medications and non-scarring alopecia, but it has not established that these medications directly damage hair follicles. Weight loss itself, reduced calorie and protein intake, nutritional changes, underlying pattern hair loss, and other factors may contribute.

For many patients, shedding improves as weight and nutrition stabilize and the normal hair-growth cycle resumes.

If you are noticing increased shedding while taking semaglutide or tirzepatide, bring it up at your next Affinity Whole Health visit. We can review your rate of weight loss, nutrition, treatment plan, and whether additional evaluation or hair-growth support may be appropriate.

Schedule your consultation today.

This content is for educational purposes only and does not constitute medical advice. Semaglutide and tirzepatide have specific FDA-approved indications and important safety considerations. Individual results vary. Hair-loss evaluation and treatment decisions should be made with a qualified healthcare provider.

Key Sources

Chris Lyons
Previous

How to Lower Hematocrit on TRT: Causes, Treatment, and When to Worry
Next

Building Muscle While Losing Fat: TRT, GLP-1 Therapy, and Body Composition